Barclays PLC Has $34,000 Holdings in Renovaro Inc. (NASDAQ:RENB)

Barclays PLC raised its holdings in Renovaro Inc. (NASDAQ:RENB) by 315.7% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 69,531 shares of the company’s stock after acquiring an additional 52,804 shares during the quarter. Barclays PLC’s holdings in Renovaro were worth $34,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the business. State Street Corp lifted its stake in Renovaro by 3.8% in the third quarter. State Street Corp now owns 1,323,832 shares of the company’s stock valued at $640,000 after buying an additional 48,114 shares during the period. Rhumbline Advisers bought a new stake in shares of Renovaro during the second quarter valued at approximately $79,000. Finally, Bank of New York Mellon Corp bought a new stake in shares of Renovaro during the second quarter valued at approximately $220,000. 71.41% of the stock is owned by institutional investors and hedge funds.

Renovaro Stock Down 5.0 %

NASDAQ RENB opened at $0.79 on Friday. The company has a market cap of $125.77 million, a price-to-earnings ratio of -0.83 and a beta of 0.65. Renovaro Inc. has a 52 week low of $0.40 and a 52 week high of $5.25. The business has a 50 day moving average price of $0.97 and a 200-day moving average price of $0.87.

Renovaro (NASDAQ:RENB) last released its quarterly earnings data on Thursday, October 10th. The company reported ($0.45) EPS for the quarter.

About Renovaro

Renovaro Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company’s product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV.